ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health - Eli Lilly

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

You will be redirected in 10 seconds.